Anand Gaurav

761 total citations
64 papers, 506 citations indexed

About

Anand Gaurav is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, Anand Gaurav has authored 64 papers receiving a total of 506 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 19 papers in Pharmacology and 15 papers in Organic Chemistry. Recurrent topics in Anand Gaurav's work include Phosphodiesterase function and regulation (20 papers), Cholinesterase and Neurodegenerative Diseases (16 papers) and Computational Drug Discovery Methods (15 papers). Anand Gaurav is often cited by papers focused on Phosphodiesterase function and regulation (20 papers), Cholinesterase and Neurodegenerative Diseases (16 papers) and Computational Drug Discovery Methods (15 papers). Anand Gaurav collaborates with scholars based in Malaysia, India and Maldives. Anand Gaurav's co-authors include Ranjit Singh, Vannajan Sanghiran Lee, Patrick Nwabueze Okechukwu, Uttam Kumar Mandal, Gabriel Akyirem Akowuah, Shalini Agarwal, Neeraj Masand, Vaishali M. Patil, Ming Tatt Lee and Mridula Sharma and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Anand Gaurav

58 papers receiving 489 citations

Peers

Countries citing papers authored by Anand Gaurav

Since Specialization

Citations

This map shows the geographic impact of Anand Gaurav's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anand Gaurav with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anand Gaurav more than expected).

Fields of papers citing papers by Anand Gaurav

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anand Gaurav. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anand Gaurav. The network helps show where Anand Gaurav may publish in the future.

Co-authorship network of co-authors of Anand Gaurav

This figure shows the co-authorship network connecting the top 25 collaborators of Anand Gaurav. A scholar is included among the top collaborators of Anand Gaurav based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anand Gaurav. Anand Gaurav is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recent Developments in Diabetes Management: Exploring Receptors, Pathways, and Compounds 2025 ·SHILAP Revista de lepidopterología ·(unknown), Vikash Jakhmola, Supriyo Saha, Anand Gaurav	1
2	Insights into biological activities profile of gingerols and shogaols for potential pharmacological applications 2025 ·Archives of Pharmacal Research ·(unknown), Anand Gaurav, Vannajan Sanghiran Lee, Nadiah Mad Nasir, Sharifuddin M. Zain, Vaishali M. Patil, Ming Tatt Lee	1
3	Herb5GluCon: A novel polyherbal formulation with dual-action inhibiting properties against oxidative stress and glycoside hydrolases – an in silico and in vitro approach 2024 ·Phytomedicine Plus ·(unknown), Patrick Nwabueze Okechukwu, Baskaran Gunasekaran, Małgorzata Jeleń, Beata Morak‐Młodawska, Gabriele Ruth Anisah Froemming, (unknown), (unknown), (unknown), (unknown), (unknown), Anand Gaurav	1
4	Identification of New Dual PDE4/5 Inhibitors Using Pharmacophore Based Virtual Screening 2023 ·Current Trends in Biotechnology and Pharmacy ·(unknown), Anand Gaurav, (unknown)	1
5	Designing of 2,3-dihydrobenzofuran derivatives as inhibitors of PDE1B using pharmacophore screening, ensemble docking and molecular dynamics approach 2023 ·Computers in Biology and Medicine ·(unknown), Anand Gaurav, Vannajan Sanghiran Lee	7
6	In vitro study of antioxidant, antigylycation, sugar hydrolysis enzyme inhibitory effect and molecular in silico docking study of angularly condensed diquinothiazines 2023 ·Journal of Molecular Structure ·Małgorzata Jeleń, (unknown), (unknown), (unknown), (unknown), Beata Morak‐Młodawska, Anand Gaurav, (unknown), Mylene M. Uy, (unknown), Patrick Nwabueze Okechukwu	7
7	Natural Products as Monoamine Oxidase Inhibitors: Potential Agents forNeurological Disorders 2023 ·Combinatorial Chemistry & High Throughput Screening ·Neetu Agrawal, (unknown), Sonia Singh, Ahsas Goyal, Anand Gaurav	5
8	Schizophrenia: The Ambiguous Mechanism behind the Disorder 2022 ·Jordan Journal of Pharmaceutical Sciences ·(unknown), Anand Gaurav	4
9	Structure-based discovery and bio-evaluation of a cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one as a phosphodiesterase 10A inhibitor 2022 ·RSC Advances ·(unknown), Anand Gaurav, Vannajan Sanghiran Lee, Baskaran Gunasekaran, Ming Tatt Lee, Patrick Nwabueze Okechukwu, Piyarat Nimmanpipug	8
10	Computational Approaches in the Discovery and Development of Therapeuticand Prophylactic Agents for Viral Diseases 2022 ·Current Topics in Medicinal Chemistry ·Anand Gaurav, Neetu Agrawal, (unknown), (unknown)	10
11	Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system 2022 ·Molecular Diversity ·(unknown), Anand Gaurav, Neeraj Masand, Vannajan Sanghiran Lee, Vaishali M. Patil	18
12	Evaluation of the Therapeutic Effect of the Traditional Herbal Medicine Atrifil and Oshagh Gum on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats 2022 ·Advances in Urology ·Fatemeh Akbari, Mohammad Azadbakht, Anand Gaurav, (unknown), (unknown), (unknown), (unknown), Aroona Chabra, (unknown)	8
13	Evaluation of the acute oral toxicity and antipsychotic activity of a dual inhibitor of PDE1B and PDE10A in rat model of schizophrenia 2022 ·PLoS ONE ·(unknown), Anand Gaurav, Ming Tatt Lee, Patrick Nwabueze Okechukwu, Piyarat Nimmanpipug, Vannajan Sanghiran Lee	10
14	In silico investigation on the probable macromolecular drug targets involved in the anti-schizophrenia activity of Nardostachys jatamansi 2022 ·Brazilian Journal of Pharmaceutical Sciences ·(unknown), Anand Gaurav, (unknown)	2
15	Comparative Studies of Palmatine with Metformin and Glimepiride on the Modulation of Insulin Dependent Signaling Pathway In Vitro, In Vivo & Ex Vivo 2022 ·Pharmaceuticals ·Patrick Nwabueze Okechukwu, Mridula Sharma, (unknown), Anand Gaurav, (unknown), Małgorzata Jeleń, Beata Morak‐Młodawska, (unknown), (unknown)	12
16	Pharmacophore Modelling and Virtual Screening Studies for the Discovery of Potential Natural Products Based PDE1B Inhibitor Lead Compounds 2021 ·Central Nervous System Agents in Medicinal Chemistry ·(unknown), Anand Gaurav	2
17	Production and Immunogenicity of a Tag-Free Recombinant Chimera Based on PfMSP-1 and PfMSP-3 Using Alhydrogel and Dipeptide-Based Hydrogels 2021 ·Vaccines ·Anand Gaurav, (unknown), Nitin Yadav, Paushali Mukherjee, Virander S. Chauhan	7
18	In Silico Investigations on the Probable Macromolecular Drug Targets Involved in the Anti-Schizophrenia Activity of Terminalia bellerica 2021 ·Letters in Organic Chemistry ·(unknown), Anand Gaurav, (unknown)	3
19	Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia 2020 ·Current Topics in Medicinal Chemistry ·(unknown), Anand Gaurav	12
20	Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor 2020 ·Heliyon ·(unknown), Anand Gaurav, Vannajan Sanghiran Lee	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact